In the BCR immune repertoire, 13 malignant-tumor-associated CDR3 clones were preferentially expressed in malignant tumor patients, while 8 benign-tumor-associated CDR3 clones were preferentially expressed in benign tumor patients (Figures 3H, I). This evidence concerns the gene BCR and cancer.